NovoCure (NVCR) Cash from Operations Growth (1y) (2015 - 2026)
NovoCure (NVCR) Cash from Operations Growth (1y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.92 Bn | 146.27 Bn | 6.27 Bn | -7.20% |
| 2 | Stryker | 119.50 Bn | 116.62 Bn | 3.81 Bn | 132.40% |
| 3 | Medtronic | 102.71 Bn | 94.54 Bn | 5.76 Bn | 6.69% |
| 4 | Boston Scientific | 69.72 Bn | 68.51 Bn | 3.61 Bn | -35.67% |
| 5 | Edwards Lifesciences | 49.24 Bn | 45.57 Bn | 1.29 Bn | -84.38% |
| 6 | GE HealthCare Technologies | 29.74 Bn | 27.67 Bn | 1.98 Bn | 16.00% |
| 7 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 122.43% |
| 8 | Dexcom | 28.96 Bn | 27.84 Bn | 750.30 Mn | 185.96% |
| 9 | Steris | 20.31 Bn | 19.88 Bn | 697.10 Mn | 28.60% |
| 10 | NovoCure | 2.03 Bn | 1.60 Bn | 135.13 Mn | 62.10% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 62.10% |
| Dec 31, 2025 | -421.70% |
| Sep 30, 2025 | 98.28% |
| Jun 30, 2025 | -826.51% |
| Mar 31, 2025 | -12.96% |
| Dec 31, 2024 | 76.29% |
| Sep 30, 2024 | 153.72% |
| Jun 30, 2024 | 92.44% |
| Mar 31, 2024 | -88.76% |
| Dec 31, 2023 | -292.72% |
| Sep 30, 2023 | -186.15% |
| Jun 30, 2023 | -244.25% |
| Mar 31, 2023 | -353.68% |
| Dec 31, 2022 | -125.74% |
| Sep 30, 2022 | -8.11% |
| Jun 30, 2022 | -39.78% |
| Mar 31, 2022 | -120.74% |
| Dec 31, 2021 | -73.07% |
| Sep 30, 2021 | -21.21% |
| Jun 30, 2021 | 105.42% |